GRAIL, Inc. (GRAL)
| Market Cap | 443.07M |
| Revenue (ttm) | 109.74M |
| Net Income (ttm) | -2.88B |
| Shares Out | 31.05M |
| EPS (ttm) | -92.87 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 336,705 |
| Open | 14.45 |
| Previous Close | 14.49 |
| Day's Range | 13.86 - 14.45 |
| 52-Week Range | 12.33 - 23.36 |
| Beta | n/a |
| Analysts | Hold |
| Price Target | n/a |
| Earnings Date | Nov 15, 2024 |
About GRAL
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illum... [Read more]
Financial Performance
In 2023, GRAIL's revenue was $93.11 million, an increase of 67.61% compared to the previous year's $55.55 million. Losses were -$1.47 billion, -72.85% less than in 2022.
Financial numbers in USD Financial StatementsNews
GRAIL Appoints Sarah Krevans to Board of Directors
MENLO PARK, Calif. , Oct. 21, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced the appointment of Sar...
Stock Picks From Seeking Alpha's September 2024 New Analysts
In September, thirty new analysts joined Seeking Alpha, offering diverse stock picks and insights, from Strong Buy to Strong Sell ratings. Highlighted picks include InMode Ltd., Intel Corporation, and...
Vieu cracks the “holy grail” of B2B sales with AI-powered business network; raises $11m as growth scales
Vieu's AI-powered Sales Graph challenges traditional social networks and CRM systems to fast-track enterprise sales pursuits. The Vieu Graph platform indexes billions of relationships and industry-spe...
GRAIL: Post-Spinoff, Illumina Maintains Control And Incentive To Support Success
GRAIL Inc., spun off from Illumina Inc. in June 2024, faces financial challenges but holds significant growth potential with its Galleri cancer-screening test. Despite a strong balance sheet, GRAIL's ...
GRAIL's Potential Turnaround: Seeking FDA Approval For Galleri
Grail's Galleri test detects over 50 cancer types early, potentially saving lives, and is progressing towards FDA approval and broader insurance coverage. The company, a spinoff from Illumina, has sig...
EU top court backs Illumina fight against EU probe into Grail deal
Europe's top court on Tuesday backed U.S. gene sequencing company Illumina's fight against EU antitrust regulators' investigation into its $7.1 billion bid for cancer diagnostic test maker Grail.
GRAIL ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(c)(4)
MENLO PARK, Calif. , Aug. 30, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted eq...
Results of GRAIL's Galleri® Multi-Cancer Early Detection Blood Test in Prostate Cancer Published in JCO Precision Oncology
Data Support Clinical Performance of Galleri to Detect More Aggressive Prostate Cancers MENLO PARK, Calif. , Aug. 29, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL) a healthcare company whose missi...
GRAIL to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
MENLO PARK, Calif. , Aug. 21, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company managemen...
GRAIL Inc. (GRAL) Q2 2024 Earnings Call Transcript
GRAIL Inc. (NASDAQ:GRAL) Q2 2024 Results Conference Call August 13, 2024 4:30 PM ET Company Participants Bob Ragusa - CEO & Director Aaron Freidin - Chief Financial Officer Joshua Ofman - President C...
Grail to cut jobs, planned hires for 2024 by about 30%
Cancer test maker Grail said on Tuesday it would reduce existing headcount and planned hires for 2024 by about 30%, as part of its restructuring program.
GRAIL Reports Second Quarter 2024 Financial Results and Provides a Strategic Update
Second Quarter Revenue Grew 43% Year-Over-Year to $32.0 Million Portfolio Prioritization and Corporate Restructure Extends Cash Runway into 2028 MENLO PARK, Calif. , Aug. 13, 2024 /PRNewswire/ -- GRA...
GRAIL to Announce Second Quarter 2024 Financial Results
MENLO PARK, Calif. , July 31, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue fin...
GRAIL Announces First Participant Enrolled in REACH Study Evaluating Clinical Impact of Galleri® Multi-Cancer Early Detection (MCED) Test in the Medicare Population
Community Health Network Has Begun Enrollment of the Prospective, Multi-Center Study to Assess the Real-World Clinical Impact of Galleri ® in Addition to Currently Recommended Cancer Screenings Study...
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL Completes Enrollment of More Than 35,000 Participants in the PATHFINDER 2 Study; Results From the First 25,000 Participants Expected in the Second Half of 2025 GRAIL Completes Final Study Visit...
Undercovered Dozen: Telus Corporation, X-FAB Silicon Foundries, GRAIL, And More
The 'Undercovered' Dozen highlights twelve ideas from the previous week on stocks with limited coverage. If you're looking for yield, two preferred stock ideas are featured, as well as other high yiel...
Illumina: Marriage Made In Hell Is (Finally) Over - Assessing Impact Of GRAIL Spin-Out
Illumina has finally completed the divestiture of GRAIL, ending a disastrous chapter in its history. The Company paid $8bn to acquire the cancer testing business it helped to create, which proved to b...
Illumina to take $1.47 bln goodwill impairment charge related to Grail in Q2
Illumina said on Thursday it will take a goodwill impairment charge of $1.47 billion in the second quarter related to the recently spun-off Grail Inc.
Illumina Completes Spin-Off Of GRAIL
On June 25, 2024, Illumina, Inc. (NASDAQ: ILMN, $208.92, Market Capitalization: $18.51 billion) announced the completion of the tax free spin-off of GRAIL, Inc. (NASDAQ: GRAL, $36.84, Market Capitaliz...
GRAIL: Ambitious Illumina Spin-Off Trading At Intriguing Valuation
GRAIL shares started trading on Nasdaq after a spin-off from Illumina, as the EU's regulatory scrutiny weighed on the prior merger. The company offers the Galleri blood test for early cancer detection...
Grail's shares fall in Nasdaq debut after spin-off from Illumina
Shares of Grail fell as much as 11.7% in their market debut on Tuesday after being spun out of gene-sequencing company Illumina.
Grail expected to be first FDA-approved multi-cancer test, says CEO Bob Ragusa
Grail CEO Bob Ragusa joins CNBC's 'Squawk Box' to discuss the company's debut on the Nasdaq, how Grail is innovating early cancer detection, and more.
Grail bets big on flagship cancer test after spin-off from Illumina
U.S. cancer diagnostic test maker Grail, which will list its shares on the Nasdaq on Tuesday after being spun out of Illumina , is betting that commercial partnerships with health systems, employers a...
GRAIL to Begin Trading on the Nasdaq Stock Exchange
MENLO PARK, Calif.--(BUSINESS WIRE)--GRAIL, Inc. (NASDAQ: GRAL, formerly GRAIL, LLC) will be listed and commence regular-way trading on the Nasdaq as of tomorrow, June 25, 2024.